



Prof. Miklos Pless

Contact

Prof. Miklos Pless
Switzerland

Publications (32)

König D, Savic Prince S, Hayoz S, Zens P, Berezowska S, Jochum W, Stauffer E, Braunersreuther V, Trachsel B, Thierstein S, Mark M, Schmid S, Curioni-Fontecedro A, Addeo A, Schmitt-Opitz I, Guckenberger M, Früh M, Betticher D, Ris H, Stupp R, Rothschild S, Bubendorf L, Pless M. Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14. *ESMO Open* 2023; 8:101595.

Papachristofilou A, Bedke J, Hayoz S, Schratzenstaller U, Pless M, Hentrich M, Krege S, Lorch A, Aebersold D, Putora P, Berthold D, Zihler D, Zengerling F, Dieing A, Mueller A, Schaer C, Biaggi C, Gillessen S, Cathomas R. Single-dose carboplatin followed by involved-node radiotherapy for stage IIA and stage IIB seminoma (SAKK 01/10): a single-arm, multicentre, phase 2 trial. *Lancet Oncol* 2022; 23:1441-1450.

Jörger M, Metaxas Y, Zaman K, Michielin O, Mach N, Bettini A, Schmitt A, Cantoni N, Caspar C, Stettler S, Malval R, Pless M, Britschgi C, Renner C, Koeberle D, Schulz J, Kopp C, Hayoz S, Stathis A, von Moos R, Swiss Group for Clinical Cancer Research (SAKK). Outcome and Prognostic Factors of COVID-19 Infection in Swiss Cancer Patients: Final Results of SAKK 80/20 (CaSA). *Cancers (Basel)* 2022; 14

Furrer K, Weder W, Eboulet E, Betticher D, Pless M, Stupp R, Krueger T, Perentes J, Schmid R, Lardinois D, Furrer M, Früh M, Peters S, Curioni-Fontecedro A, Stahel R, Rothschild S, Hayoz S, Opitz I. Extended resection for potentially operable patients with stage III non-small cell lung cancer after induction treatment. *J Thorac Cardiovasc Surg* 2022; 164:1587-1602.e5.

Rothschild S, Cathomas R, Ochsenbein A, Janthur W, Waibel C, Mach N, Froesch P, Buess M, Bohanes P, Godar G, Rusterholz C, Gonzalez M, Pless M, Mark M, Peters S, Zippelius A, Eboulet E, Savic Prince S, Betticher D, Bettini A, Früh M, Jörger M, Lardinois D, Gelpke H, Mauti L, Britschgi C, Weder W, Swiss Group for Clinical Cancer Research (SAKK). SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial. *J Clin Oncol* 2021; 39:2872-2880.

Mark M, Früh M, Biaggi-Rudolf C, Weindler S, Baudoux N, Schwitler M, Wannesson L, Jörger M, Metaxas Y, Schneider M, Friedlaender A, Burmeister H, Janthur W, Rothschild S, Pless M, Addeo A, Eboulet E, Froesch P, Swiss Group for Clinical Cancer Research (SAKK). SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2. *Cancer Immunol Immunother* 2020

Glatzer M, Pless M, Pederiva S, Pestalozzi B, Berger M, Inauen R, Winterhalder R, Montemurro M, Horber D, Putora P. Choice of first line systemic treatment in pancreatic cancer among national experts. *Pancreatology* 2020; 20 (2020): 686-690.

Molina-Vila M, Ponce Aix S, Carcereny E, Früh M, Pless M, Popat S, Cuffe S, Bidoli P, Kammler R, Roschitzki-Voser H, Tsourti Z, Karachaliou N, Palmero R, Massutí B, Stahel R, Dafni U, Jordana-Ariza N, Balada-Bel A, Garzón-Ibáñez M, García-Peláez B, Mayo-de-Las-Casas C, Felip E, Curioni Fontecedro A, Gautschi O, Peters S, Rosell R. Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial. *J Thorac Oncol* 2019; 15:416-425.

Papachristofilou A, Kallen K, Fotin-Mieczek M, Schröder A, Scheel B, Muth A, Seibel T, Stosnach C, Doener F, Hong H, Koch S, Gnad-Vogt U, Griesinger F, Geißler M, Bischoff H, Hipp M, Klinkhardt U, Früh M, Sebastian M, Weiss C, Pless M, Cathomas R, Hilbe W, Pall G, Wehler T, Alt J, Zippelius A. Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer. *J Immunother Cancer* 2019; 7:38.

Früh M, Guckenberger M, Rothschild S, Lardinois D, Mach N, Mark M, Gautschi O, Thierstein S, Biaggi Rudolf C, Weder W, Stahel R, Matzinger O, Betticher D, Stupp R, Xyrafas A, Peters S, Ris H, Mirimanoff R, Ochsenbein A, Schmid R, Pless M. Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long-Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01). *J Thorac Oncol* 2018

Metaxas Y, Froesch P, Löffler-Baumann M, Pratsch-Peter S, Russell P, Mingrone W, Savic S, Thapa B, Früh M, Pless M, von Moos R, Mauti L, O'Byrne K, Petrusch U, Wolleb S, Rivalland G, Klingbiel D, Kao S, Schmid S, Nowak A, Gautschi O, Bartnick T, Hughes B, Bouchaab H, Rothschild S, Pavlakis N, John T. Brief Report: Pembrolizumab as palliative immunotherapy in malignant pleural mesothelioma. *J Thorac Oncol* 2018

Balmelli C, Stenner F, Pless M, Weidner S, Zimmermann S, GÜthner C, Cristina V, Cathomas R, Feuerlein K, Siano M, Railic N, Rothschild S. Lenvatinib in Advanced Radioiodine-Refractory Thyroid Cancer – A Retrospective Analysis of the Swiss Lenvatinib Named Patient Program. *J Cancer* 2018; 9:250-255.

Rosell R, Shah R, Porta R, Majem M, Gómez-Codina J, Camps C, Thomas M, Rauch D, Barlesi F, Hanrahan E, Kammler R, Stahel R, Molina-Vila M, Shames D, Tam R, Karachaliou N, Kassapian M, Rabaglio M, Ruepp B, Coate L, Puente J, Aix S, Palmero R, Massutí B, Peters S, Gautschi O, Curioni-Fontecedro A, Felip E, Dafni U, Carcereny E, Früh M, Reguart N, Froesch P, Favaretto A, Bidoli P, Cuffe S, Kotsakis A, Popat S, Pless M, BELIEF collaborative group. Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. *Lancet Respir Med* 2017; 5:435-444.

Gautschi O, Ochsenbein A, Mach N, Biaggi C, Schneider M, Zander T, Froesch P, Peters S, Pless M, Rauch D, Cathomas R, Stahel R, Früh M, Betticher D, Zippelius A, Matter-Walstra K, Li Q, Rothschild S. Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial. *Clin Lung Cancer* 2016

Pless M, Bijelovic M, Ochsenbein A, Meier U, Mamot C, Rauch D, Gautschi O, Betticher D, Mirimanoff R, Peters S, Roth A, Zippelius A, Stupp R, Ris H, Stahel R, Weder W, Thierstein S, Gerard M, Xyrafas A, Früh M, Cathomas R. Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial. *Lancet* 2015; 386:1049-56.

Mamot C, Zucca E, Dirnhofer S, Rusterholz C, Biaggi C, Samarin A, Hany T, Gigli F, Krasniqi F, Bargetzi M, Pless M, Mey U, Driessen C, Pabst T, Renner C, Hitz F, Klingbiel D, Martinelli G. Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07). *J Clin Oncol* 2015; 33:2523-9.

Gautschi O, Savic S, Jaggi R, Leibundgut E, Largiadèr C, Brutsche M, Pilop C, Stalder L, Pless M, Ochsenbein A, Bubendorf L, Feilchenfeldt J, Rauch D, Mach N, Rothschild S, Li Q, Stahel R, Zippelius A, Cathomas R, Früh M, Betticher D, Peters S, Swiss Group for Clinical Cancer Research. Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09. *Clin Lung Cancer* 2015; 16:358-65.

Baty F, Brutsche M, Pless M, Zappa F, Crowe S, Bubendorf L, Gautschi O, Rauch D, Cathomas R, Dröge C, Betticher D, Früh M, Rothschild S, Swiss Group for Clinical Cancer Research. EGFR Exon-Level Biomarkers of the Response to Bevacizumab/Erlotinib in Non-Small Cell Lung Cancer. *PloS one* 2013; 8:e72966.

Strebel R, Winterhalder R, Morant R, Pless M, Huber U, Fehr M, Gillessen Sommer S, Schmid H, Sulser T, Cathomas R. Multidisciplinary care in patients with prostate cancer: room for improvement. *Support Care Cancer* 2013; 21:2327-33.

Bontognali S, Pless M, Brutsche M, Fischer C, Rochlitz C, Buess M. Analysis of the EGFR Mutation Status in Head and Neck Squamous Cell Carcinoma before Treatment with Gefitinib. *Onkologie* 2013; 36:161-6.

Uster A, Ruefenacht U, Ruehlin M, Pless M, Siano M, Haefner M, Imoberdorf R, Ballmer P. Influence of a nutritional intervention on dietary intake and quality of life in cancer patients: a randomized controlled trial. *Nutrition* 2013; 29:1342-9.

Gautschi O, Stahel R, Carbone D, Na K, Hsu Schmitz S, Bubendorf L, Baty F, Brutsche M, Pless M, Zappa F, Roder J, Grigorieva J, Roder H, Peters S, Crowe S, Dingemans A, Smit E. VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: pooled analysis of SAKK19/05 and NTR528. *Lung Cancer* 2012; 79:59-64.

Cathomas R, Gillessen Sommer S, von Moos R, Schiess R, Pless M, Berthold D, Siciliano D, Winterhalder R, Droege C, Cotting D, Brauchli P, Betticher D, Jaggi R, Bubendorf L, Klingbiel D, Rothermundt C, Swiss Group for Clinical Cancer Research SAKK. Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07). *Clin Cancer Res* 2012; 18:6049-57.

Früh M, Pless M, Fustier P, Küttel E, Simcock M, Rauch D, Krasniqi F, Erdmann A, Mamot C, Zippelius A, Tscherry G, Siano M, Cathomas R, Swiss Group for Clinical Cancer Research. Carboplatin and paclitaxel plus ASA404 as first-line chemotherapy for extensive-stage small-cell lung cancer: a multicenter single arm phase II trial (SAKK 15/08). *Clin Lung Cancer* 2012; 14:34-9.

Pesce G, Bernhard J, Kotrubczik N, D'Addario G, Pilop C, Weber D, Bodis S, Pless M, Mayer M, Cathomas R, Peters S, Klingbiel D, Ribi K, Zouhair A, von Moos R, Schlaeppli M, Caspar C, Fischer N, Anchisi S, Stupp R. Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 70/03). *Eur J Cancer* 2011; 48:377-84.

Ruhstaller T, Brauchli P, Inauen R, Widmer L, Mingrone W, Gautschi O, Rauch D, Schneider P, Montemurro M, Moosmann P, von Moos R, Kranzbuehler H, Dietrich D, Pless M, Hess V. Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial (SAKK 75/06). *J Clin Oncol* 2011; 29:626-31.

Baty F, Tamm M, Kehren J, Buess M, Budach W, Marrer E, Savic S, Bubendorf L, Pless M, Schumacher M, Kaiser S, Facompre M, Brutsche M. Gene profiling of clinical routine biopsies and prediction of survival in non-small cell lung cancer. *American journal of respiratory and critical care medicine* 2010; 181:181-8.

Simcock M, Furrer H, Hirschel B, Vernazza P, Sendi P, Rickenbach M, Bucher H, Battegay M, Koller M, Moirandat-Rytz S, Terziroli B, Blasko M, Karrer U, Bertisch B, Pless M, Blumer L, Vora S, Robinson J, Bernasconi E, Swiss HIV Cohort Study. Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study. *Antiviral therapy* 2007; 12:931-9.

Chhajed P, Baty F, Pless M, Somandin S, Tamm M, Brutsche M. Outcome of treated advanced non-small cell lung cancer with and without central airway obstruction. *Chest* 2006; 130:1803-7.

Jermann M, Bauer J, Rhyner K, Egli F, Morant R, Gillessen Sommer S, Jörger M, Cerny T, Salzberg M, Stahel R, Pless M. A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma. *Cancer chemotherapy and pharmacology* 2006; 57:533-9.

Waechter F, Passweg J, Tamm M, Brutsche M, Herrmann R, Pless M. Significant progress in palliative treatment of non-small cell lung cancer in the past decade. *Chest* 2005; 127:738-47.

Betticher D, Stahel R, Weder W, Stupp R, Egli F, Furrer M, Honegger H, Wernli M, Cerny T, Spiliopoulos A, Roth A, Hsu Schmitz S, Tötsch M, Hansen E, Joss C, von Briel C, Schmid R, Pless M, Habicht J, Ris H. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2003; 21:1752-9.

Projects (1)

Circulating micro-RNA profiling in patients with advanced non-squamous non small-cell lung cancer receiving bevacizumab/erlotinib first-line treatment followed by platinum-based chemotherapy at disease progression (SAKK 19/05)

Fundamental Research - Apr 1, 2012 - Sep 1, 2013

Completed

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch